BEGEV Salvage Regimen Linked to High Complete Remission Rates
5-year results from that a study on BEGV have confirmed its benefits in classical Hodgkin lymphoma.
All articles by Agata Boxe
Tivozanib Shows Superior Safety Profile Across TKIs in Metastatic Renal Cell Carcinoma
For the study, researchers conducted a literature review and network meta-analysis of phase 2/3 randomized controlled trials of approved first-line TKI therapies for mRCC.
Open Radical Nephrectomy for RCC May Increase Circulating Tumor Cells
The investigators observed significantly higher postoperative CTC counts in the open radical nephrectomy group compared with the other 3 groups in the study.
New Vaccine Could Delay ADT Use in Stage D0 Prostate Cancer
If the vaccine is shown to work, it may help delay the use of ADT in such patients, Dr Maeng said.
Oncologists Debate Using Maintenance Bevacizumab in Stage IIIc Ovarian Cancer
In a recent paper published in the Journal of Clinical Oncology, the authors recommended using adjuvant and maintenance bevacizumab to treat a patient with stage IIIc ovarian cancer following an optimal (R0) resection.
Ibrutinib Shown to Cross the Blood-Brain Barrier in CNS Lymphoma
The authors proved that the drug was able to cross the blood-brain barrier in a concentration that was effective.
Previously Hidden FDA Data Reveal a Multitude of Adverse Events Linked to Breast Implants
Why were adverse events reported through an alternative reporting channel as opposed to a more transparent means?
New Trial Attempts to Make Genetic Counseling and Testing More Accessible
The researchers wrote that “genetic counseling must be further explored to find an optimal balance of clinical quality with increased access and financial sustainability.”
Research Examines Breast Cancer Susceptibility Genes in Hispanic Women and Other Diverse Populations
The presence of CHEK2 or PALB2 variants in Hispanic women is enough to warrant the addition of an annual breast MRI, said study authors.
Analysis Sheds Light on Bevacizumab “Reversals” in Glioblastoma
Improvements to PFS and “clinically meaningful reductions in daily corticosteroid use” were said to be linked to the addition of bevacizumab in glioblastoma.
Next post in Brain Cancer
